EGFR mutant subset analysis from ARCHER 1009: A randomized double blind phase 3 efficacy and safety study of dacomitinib versus erlotinib for the treatment of advanced non-small cell lung cancer (NSCLC)
L. Paz-Ares
EGFR mutant subset analysis from ARCHER 1009: A randomized double blind phase 3 efficacy and safety study of dacomitinib versus erlotinib for the treatment of advanced non-small cell lung cancer (NSCLC)
L. Paz-Ares